Novartis announced results from a phase 3 trial for Signifor LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.
The trial was a multicenter, randomized, double blind trial examining pasireotide LAR 40 mg or 60 mg vs. continued open-label treatment with octreotide LAR 30 mg or lanreotide Autogel 120 mg (the control group) for 24 weeks.
The trial included 198 patients with inadequately controlled acromegaly on maximum approved doses of octreotide LAR or lanreotide Autogel for at least 6 months, regardless of prior surgical status. The primary endpoint of this study was the proportion of patients achieving biochemical control as measured by the mean GH levels of <2.5 mcg/L and normalized insulin-like growth factor I (IGF-1) at 24 weeks.
Patients taking pasireotide long-acting release (LAR) achieved greater disease control when compared with continued treatment with the standard somatostatin analogue therapies, octreotide LAR or lanreotide Autogel.
IGF-1 normalization was achieved by 24.6% and 26.2% of patients taking pasireotide LAR 40 mg and 60 mg, respectively (95% CI, 14.8–36.9; P<0.001 and 95% CI, 16.0–38.5; P<0.001, respectively), and was not achieved by any patients in the control arm (95% CI, 0–5.3).
Additionally, 35.4% and 43.1% of patients in the pasireotide LAR 40 mg and 60 mg arms, respectively (95% CI, 23.9–48.2 and 95% CI, 30.8–56.0, respectively), had mean GH levels of <2.5 mcg/L compared to 13.2% in the control arm (95% CI, 6.2–23.6).
Signifor is already approved for the treatment of adult patients with Cushing’s disease for whom pituiraty surgery is not an option or has not been curative.
For more information call (888) 669-6682 or visit Novartis.com.
This article originally appeared on MPR